Full-Time
Quality Assurance Associate
Granules
501-1,000 employees
Vertically integrated API and dosage manufacturer
Compensation Overview
$50k - $60k/yr
Manassas, VA, USA
In Person
 Biology & Biotech (1) |
|---|
Get referred to Granules
See people who can refer or advise you
- Experience in a good manufacturing practice environment is preferred.
- Microsoft Excel proficiency.
- Communication skills and attention to detail.
- Review and release batch records.
- Review and approve shipper labels, expiry forms, lot memos, and print proofs.
- Approve new master batch records and change controls.
- Track batch record releases.
- Release finished products, labels, and cartons in SAP.
- Sample, inspect, and release incoming labels and cartons.
- Review and release Kenvue batches and upload the documents in the SAP portal.
- Log and report weekly Kenvue batch releases.
- Prepare annual product reviews.
- Prepare and submit annual report data to the GIL team for Food and Drug Administration submission.
- Create stability initiation forms.
- Collect and ship samples to customers.
- Manage customer queries.
- Share change controls with customers and follow up.
- Log change controls.
- Provide role-based training to new employees.
- Support audits by reviewing documents for accuracy and compliance.
- Experience in a good manufacturing practice environment.
Granules India makes APIs, PFIs, and finished dosages, using large-scale, vertically integrated plants that control production from base chemicals to final medicines. Its products include common off-patent APIs like Paracetamol, Ibuprofen, Metformin, and Guaifenesin, and it is expanding into more complex areas such as MUPS, oncology, and peptide therapies with US FDA approvals. The company differentiates itself through full vertical integration, large scale, and a global manufacturing footprint that supports both contract manufacturing and its own branded products, offering supply security and cost competitiveness. Its goal is to deliver reliable, affordable medicines to customers worldwide while growing capabilities in complex therapies and pursuing sustainable practices like green chemistry.
Company Size
501-1,000
Company Stage
N/A
Total Funding
N/A
Headquarters
N/A
Founded
2014
Get referred to Granules
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q3 FY26 revenue rose 22% to INR 1,388 crores, led by North America and Europe.
- July 2026 inspections at Genome Valley and Chantilly improved regulatory optionality and capacity.
- Europe grew 151% year-on-year in FY26, while peptide CDMO opened a new revenue vertical.
What critics are saying
- FDA warning letter dated February 26, 2025 threatens Gagillapur product approvals until remediation closes.
- Reuters on April 9, 2026 reported record-keeping and contamination concerns still burden management.
- Any second FDA action at Gagillapur can shut U.S. launches and damage Granules' generics franchise.
What makes Granules unique
- Granules integrates APIs, PFIs, and dosages, preserving cost control across the value chain.
- February 2025 Senn Chemicals acquisition adds peptide CDMO capabilities and European regulated-market access.
- Granules shipped in 80 countries and won 94 approvals by August 2026.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Flexible Work Hours